Accès gratuit
Méd. Intensive Réa.
Volume 25, Numéro 6, Novembre 2016
Néphrologie et métabolisme
Page(s) 628 - 641
Section Mise au point / Update
Publié en ligne 13 octobre 2016
  • Disayabutr S, Calfee CS, Collard HR, Wolters PJ (2015) Interstitial lung diseases in the hospitalized patient. BMC Med 13:245 [CrossRef] [PubMed] [Google Scholar]
  • Collard HR, Moore BB, Flaherty KR, et al (2007) Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176:636–43 [CrossRef] [PubMed] [Google Scholar]
  • Park IN, Kim DS, Shim TS, et al (2007) Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 132:214–20 [CrossRef] [PubMed] [Google Scholar]
  • Webber MP, Moir W, Zeig-Owens R, et al (2015) Nested case-control study of selected systemic autoimmune diseases in World Trade Center rescue/recovery workers. Arthritis Rheumatol 67:1369–76 [CrossRef] [PubMed] [Google Scholar]
  • Dobloug C, Garen T, Bitter H, et al (2015) Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis 74:1551–6 [CrossRef] [PubMed] [Google Scholar]
  • Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–7 [CrossRef] [PubMed] [Google Scholar]
  • Oddis CV, Rider LG, Reed AM, et al (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52:2607–15 [CrossRef] [PubMed] [Google Scholar]
  • Marguerie C, Bunn CC, Beynon HL, et al (1990) Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 77:1019–38 [CrossRef] [PubMed] [Google Scholar]
  • Connors GR, Christopher-Stine L, Oddis CV, Danoff SK (2010) Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138:1464–74 [CrossRef] [PubMed] [Google Scholar]
  • Schiffenbauer A (2014) Imaging: seeing muscle in new ways. Curr Opin Rheumatol 26:712–6 [CrossRef] [PubMed] [Google Scholar]
  • Teixeira A, Cherin P, Demoule A, et al (2005) Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies. Neuromuscul Disord 15:32–9 [CrossRef] [PubMed] [Google Scholar]
  • Marie I, Hachulla E, Cherin P, et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47:614–22 [CrossRef] [PubMed] [Google Scholar]
  • Fathi M, Vikgren J, Boijsen M, et al (2008) Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 59:677–85 [CrossRef] [PubMed] [Google Scholar]
  • Chua F, Higton AM, Colebatch AN, et al (2012) Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology (Oxford) 51:1870–6 [CrossRef] [PubMed] [Google Scholar]
  • Marie I, Josse S, Hatron PY, et al (2013) Interstitial lung disease in anti-Jo1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 65:800–8 [CrossRef] [PubMed] [Google Scholar]
  • Hallowell RW, Ascherman DP, Danoff SK (2014) Pulmonary manifestations of polymyositis/dermatomyositis. Semin Respir Crit Care Med 35:239–48 [CrossRef] [PubMed] [Google Scholar]
  • Lega JC, Fabien N, Reynaud Q, et al (2014) The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 13:883–91 [CrossRef] [PubMed] [Google Scholar]
  • Hervier B, Devilliers H, Stanciu R, et al (2012) Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 12:210–7 [CrossRef] [PubMed] [Google Scholar]
  • Aggarwal R, Cassidy E, Fertig N, et al (2014) Patients with non-Jo1 anti-tRNA-synthetase autoantibodies have worse survival than Jo1 positive patients. Ann Rheum Dis 73:227–32 [CrossRef] [PubMed] [Google Scholar]
  • Tillie-Leblond I, Wislez M, Valeyre D, et al (2008) Interstitial lung disease and anti-Jo1 antibodies: difference between acute and gradual onset. Thorax 63:53–9 [CrossRef] [PubMed] [Google Scholar]
  • Sarkar K, Weinberg CR, Oddis CV, et al (2005) Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum 52:2433–8 [CrossRef] [PubMed] [Google Scholar]
  • Douglas WW, Tazelaar HD, Hartman TE, et al (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164:1182–5 [CrossRef] [PubMed] [Google Scholar]
  • Chartrand S, Swigris JJ, Peykova L, et al (2016) A multidisciplinary evaluation helps identify the antisynthetase syndrome in patients presenting as idiopathic interstitial pneumonia. J Rheumatol 43:887–92 [CrossRef] [PubMed] [Google Scholar]
  • Friedman AW, Targoff IN, Arnett FC (1996) Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 26:459–67 [CrossRef] [PubMed] [Google Scholar]
  • Hervier B, Uzunhan Y, Hachulla E, et al (2011) Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies. Eur Respir J 37:714–7 [CrossRef] [PubMed] [Google Scholar]
  • Hamaguchi Y, Fujimoto M, Matsushita T, et al (2013) Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One 8:e60442 [CrossRef] [PubMed] [Google Scholar]
  • Yoshifuji H, Fujii T, Kobayashi S, et al (2006) Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 39:233–41 [CrossRef] [PubMed] [Google Scholar]
  • Stanciu R, Guiguet M, Musset L, et al (2012) Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use. J Rheumatol 39:1835–9 [CrossRef] [PubMed] [Google Scholar]
  • Mukae H, Ishimoto H, Sakamoto N, et al (2009) Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136:1341–7 [CrossRef] [PubMed] [Google Scholar]
  • Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, et al (2003) Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 22:245–50 [CrossRef] [PubMed] [Google Scholar]
  • Moghadam-Kia S, Oddis CV, Sato S, et al (2016) Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken) 68:689–94 [CrossRef] [PubMed] [Google Scholar]
  • Uzunhan Y, Nunes H, Leroux G, et al (2013) Dermato-pulmonary syndrome associated with MDA5 antibodies: report of the first French series. Eur Respir J 42:P5114 [Google Scholar]
  • Travis WD, Costabel U, Hansell DM, et al (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733–48 [CrossRef] [PubMed] [Google Scholar]
  • Debray MP, Borie R, Revel MP, et al (2015) Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. Eur J Radiol 84:516–23 [CrossRef] [PubMed] [Google Scholar]
  • Yousem SA, Schneider F, Bi D, Oddis C, Gibson K, Aggarwal R (2014) The pulmonary histopathologic manifestations of the anti-PL7/antithreonyl transfer RNA synthetase syndrome. Hum Pathol 45:1199–204 [CrossRef] [PubMed] [Google Scholar]
  • Schneider F, Aggarwal R, Bi D, Gibson K, Oddis C, Yousem SA (2015) The pulmonary histopathology of anti-KS transfer RNA synthetase syndrome. Arch Pathol Lab Med 139:122–5 [CrossRef] [PubMed] [Google Scholar]
  • Fujisawa T, Hozumi H, Kono M, et al (2014) Prognostic factors for myositis-associated interstitial lung disease. PLoS One 9:e98824 [CrossRef] [PubMed] [Google Scholar]
  • Leslie KO, Trahan S, Gruden J (2007) Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med 28:369–78 [CrossRef] [PubMed] [Google Scholar]
  • Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63:3439–47 [CrossRef] [PubMed] [Google Scholar]
  • Zou J, Guo Q, Chi J, et al (2015) HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients. Clin Rheumatol 34:707–14 [CrossRef] [PubMed] [Google Scholar]
  • Le Goff B, Cherin P, Cantagrel A, et al (2009) The pulmonary histopathologic manifestations of the anti-PL7/antithreonyl transfer RNA synthetase syndrome. Arthritis Rheum 61:108–18 [CrossRef] [PubMed] [Google Scholar]
  • Ma X, Chen Z, Hu W, et al (2016) Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol 35:489–93 [CrossRef] [PubMed] [Google Scholar]
  • Kono H, Inokuma S, Nakayama H, Suzuki M (2000) Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. Ann Rheum Dis 59:372–6 [CrossRef] [PubMed] [Google Scholar]
  • Rodrigues AJ, Jacomelli M, Scordamaglio PR, Figueiredo VR (2012) Spontaneous pneumomediastinum associated with laryngeal lesions and tracheal ulcer in dermatomyositis. Rev Bras Reumatol 52:796–9 [PubMed] [Google Scholar]
  • Hervier B, Meyer A, Dieval C, et al (2013) Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival Eur Respir J 42:1271–82 [CrossRef] [PubMed] [Google Scholar]
  • Xu Y, Yang CS, Li YJ, et al (2016) Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol 35:113–6 [CrossRef] [PubMed] [Google Scholar]
  • Ikeda S, Arita M, Misaki K, et al (2015) Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study. BMC Pulm Med 15:78 [CrossRef] [PubMed] [Google Scholar]
  • Richards TJ, Eggebeen A, Gibson K, et al (2009) Characterization and peripheral blood biomarker assessment of anti-Jo1 antibody-positive interstitial lung disease. Arthritis Rheum 60:2183–92 [CrossRef] [PubMed] [Google Scholar]
  • Tanaka A, Tsukamoto H, Mitoma H, et al (2015) Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis. Arthritis Res Ther 17:27 [CrossRef] [PubMed] [Google Scholar]
  • Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V (2015) Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 24:216–38 [CrossRef] [PubMed] [Google Scholar]
  • Marie I, Dominique S, Janvresse A, et al (2012) Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 106:581–7 [CrossRef] [PubMed] [Google Scholar]
  • Allenbach Y, Guiguet M, Rigolet A, et al (2015) Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label Phase II Trial. PLoS One 10:e0133702 [CrossRef] [PubMed] [Google Scholar]
  • Sharp C, McCabe M, Dodds N, et al (2016) Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology (Oxford) 55:1318–24 [CrossRef] [PubMed] [Google Scholar]
  • Moghadam-Kia S, Aggarwal R, Oddis CV (2015) Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol 11:1265–75 [CrossRef] [PubMed] [Google Scholar]
  • Schnabel A, Reuter M, Biederer J, et al (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 32:273–84 [CrossRef] [PubMed] [Google Scholar]
  • Yamasaki Y, Yamada H, Yamasaki M, et al (2007) Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 46:124–30 [CrossRef] [PubMed] [Google Scholar]
  • Morganroth PA, Kreider ME, Werth VP (2010) Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 62:1496–501 [CrossRef] [PubMed] [Google Scholar]
  • Fischer A, Brown KK, Du Bois RM, et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40:640–6 [CrossRef] [PubMed] [Google Scholar]
  • Kurita T, Yasuda S, Oba K, et al (2015) The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford) 54:39–44 [CrossRef] [PubMed] [Google Scholar]
  • Ge Y, Peng Q, Zhang S, Zhou H, Lu X, Wang G (2015) Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol 34:99–105 [CrossRef] [PubMed] [Google Scholar]
  • Patwa HS, Chaudhry V, Katzberg H, et al (2012) Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 78:1009–15 [CrossRef] [PubMed] [Google Scholar]
  • Dalakas MC, Illa I, Dambrosia JM, et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000 [CrossRef] [PubMed] [Google Scholar]
  • Bakewell CJ, Raghu G (2011) Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 139:441–3 [CrossRef] [PubMed] [Google Scholar]
  • Suzuki Y, Hayakawa H, Miwa S, et al (2009) Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 187:201–6 [CrossRef] [PubMed] [Google Scholar]
  • Miller FW, Leitman SF, Cronin ME, et al (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326:1380–4 [CrossRef] [PubMed] [Google Scholar]
  • Ideura G, Hanaoka M, Koizumi T, et al (2007) Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med 101:1406–11 [CrossRef] [PubMed] [Google Scholar]
  • Ameye H, Ruttens D, Benveniste O, et al (2014) Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort. Transplant Proc 46:3147–53 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.